IREN
IREN Limited
There isn't enough reported data to score IREN yet.
IVZ
Invesco Ltd.
IVZ lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
IVZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| N/A | |
| N/A |
IVZ's revenue is currently healthy, but its profitability is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IVZ.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
IVZ PE Valuation
IVZ has no meaningful PE right now: it lost money over the past year.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
IVZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
IVZ has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IVZ has the stronger earnings trend. Trailing diluted EPS is down 347% for IREN versus IVZ down 176%.
IVZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q1 2025 | $1.25 | +$1.99 |
| Q4 2024 | $1.18 | +$1.91 |
| Q3 2024 | -$0.91 | -169% |
| Q2 2024 | -$0.74 | -152% |
| Q1 2024 | -$0.74 | -154% |
| Q4 2023 | -$0.73 | -149% |
| Q3 2023 | $1.31 | -34% |
| Q2 2023 | $1.41 | -39% |
IVZ is still losing money, but less than at its worst: $0.69 per share over the past year, against $0.91 at its worst in late 2024.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
IVZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +14% |
| Q2 2026 | $1.8B | +20% |
| Q1 2026 | $1.7B | +14% |
| Q4 2025 | $1.7B | +6.2% |
| Q3 2025 | $1.6B | +8.2% |
| Q2 2025 | $1.5B | +2.2% |
| Q1 2025 | $1.5B | +3.7% |
| Q4 2024 | $1.6B | +13% |
IVZ's revenue has grown year over year for 11 quarters in a row: $1.9B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +6.8 points |
| Q2 2026 | 20% | +5.8 points |
| Q1 2026 | 19% | +1 points |
| Q4 2025 | -86% | -106 points |
| Q3 2025 | 17% | +9.9 points |
| Q2 2025 | 14% | +0.2 points |
| Q1 2025 | 18% | +3.7 points |
| Q4 2024 | 20% | +96 points |
IVZ has the edge over IREN on profitability, with a higher operating margin.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
IVZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $442.8M | -24% |
| Q2 2026 | $703.7M | +33% |
| Q1 2026 | $198.4M | +$306.4M |
| Q4 2025 | $432.2M | +33% |
| Q3 2025 | $586.4M | +43% |
| Q2 2025 | $530.4M | +15% |
| Q1 2025 | -$108M | -$32.6M |
| Q4 2024 | $323.9M | -52% |
IVZ has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
IVZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.9M shares |
| 1 year | -0.5% | -2.1M shares |
| 3 years | -1.4% | -6.3M shares |
| 5 years | -2.9% | -13.7M shares |
| Available history | +2.7% | +12M shares |
IVZ has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $75M |
| Q2 2026 | $50.4M |
| Q1 2026 | $69.2M |
| Q4 2025 | $25.8M |
| Q3 2025 | $29.2M |
| Q2 2025 | $25.5M |
| Q1 2025 | $43.1M |
| Q4 2024 | $26M |
IVZ spent $220M buying back its own shares over the past year, up 78% from the year before.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
IVZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | -0.1x | Net Cash |
| Q3 2023 | 0.2x | Very low |
| Q2 2023 | 0.4x | Very low |
| Q1 2023 | 0.5x | Very low |
| Q4 2022 | 0.0x | Very low |
IVZ's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like IVZ.
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
IVZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 11.7 | Oversold |
IVZ's weekly RSI is 48 (neutral) and its Stochastic is 12 (oversold).
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
IVZ PE vs Financial Services Sector
| Metric | IVZ | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IVZ has no meaningful PE right now: it lost money over the past year.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
IVZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.2% below |
| 20 week MA | $30.0 | 5.2% below |
| 50 week MA | $27.8 | 2.3% above |
| 100 week MA | $23.2 | 23% above |
| 200 week MA | $19.7 | 45% above |
IVZ has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.
IVZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.8 | $17.6 | -1.2% |
| 2021 | $17.6 | $23.3 | +33% |
| 2022 | $23.3 | $18.4 | -21% |
| 2023 | $18.4 | $17.8 | -2.9% |
| 2024 | $17.8 | $17.7 | -0.9% |
| 2025 | $17.7 | $27.0 | +52% |
| 2026 YTD | $27.0 | $28.5 | +5.6% |
IVZ has the edge over IREN on returns for 2026, with the stronger performance.